S. Kalyanasundaram, Managing Director, GlaxoSmithKline, India and Vice President of South Asia GSK International, said: “We are pleased to enter into this co-promotion agreement with Eisai to facilitate the launch of Paritec in the Indian pharmaceutical market.”
GSK promotes a range of ethical formulations and is focussed in therapeutic areas of respiratory, dermatology and vaccines, besides having a presence in the areas of gastroenterology, dietary supplements, gynecology, neurology, cardiovascular and intensive care.
Eisai is a Japan-based company engaged in the discovery, development and marketing of pharmaceutical products for global usage.